Positrigo Launches BrainPET Accelerator Program in U.S.

Why It Matters

Bringing advanced brain PET to neurology offices accelerates early diagnosis of neurodegenerative diseases and opens a new revenue stream for outpatient practices.

Key Takeaways

• Compact BrainPET system fits neurology offices
• Radiotracer supply handled without on-site cyclotron
• Full regulatory, licensing, and safety support included
• Reimbursement assistance accelerates revenue generation
• Enables early diagnosis of neurodegenerative diseases

Pulse Analysis

Positron emission tomography has long been a cornerstone of functional brain imaging, yet its deployment has been confined to large academic hospitals because of expensive scanners, cyclotrons, and complex regulatory requirements. In recent years, the healthcare industry has pursued point‑of‑care solutions that shrink equipment footprints and simplify logistics, mirroring trends seen in cardiac imaging and portable ultrasound. This shift is driven by the need for faster diagnostic turnaround, improved patient convenience, and the growing prevalence of neurodegenerative disorders that demand early, accurate assessment.

Against this backdrop, Swiss‑based Positrigo introduced the BrainPET Accelerator Program, delivering a turnkey brain‑PET NeuroLF system directly to U.S. neurology practices. The bundled offering covers hardware installation, on‑demand radiotracer procurement, licensing assistance, and a revenue‑cycle service that guides practices through reimbursement codes. By offloading the technical and compliance burden, clinics can integrate amyloid, tau, or FDG scans into routine visits without building a dedicated radiochemistry lab. The model also includes remote image interpretation by nuclear‑medicine specialists, ensuring diagnostic quality while preserving the practice’s workflow.

The program’s launch could reshape the market for functional neuroimaging by expanding the addressable customer base beyond tertiary centers. Early adopters stand to gain a competitive edge in diagnosing Alzheimer’s disease, Lewy‑body dementia, and other cognitive disorders, potentially improving treatment pathways and payer relationships. Competitors such as Siemens Healthineers and GE Healthcare are also exploring compact PET solutions, but Positrigo’s end‑to‑end service differentiates it through reduced capital outlay and ongoing support. If uptake accelerates, the U.S. brain‑PET market may see a surge in point‑of‑care deployments, driving further innovation and cost efficiencies.